Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter phase II trial of lenalidomide, cyclophosphamide and dexamethasone in newly diagnosed primary systemic (AL) amyloidosis patients not eligible for transplant
2009-017707-28Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- May 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide, cyclophosphamide and dexamethasone in light-chain amyloidosis, sponsored by Fundación PETHEMA. Primary endpoints: Hematologic response rate and Organ response rate. Started May 2010; status: completed.
02
Drugs
lenalidomidecyclophosphamidedexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2009-017707-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017707-28.